Publications

The publication of research results is a fundamental requirement for improving treatment concepts across the board. iOMEDICO supports the international guidelines on transparency and publication of medical research results.

We regularly present our data at national and international conferences. Our publications appear in scientifically renowned, international journals. Authors are principal investigators, investigators with a high number of participating patients, and iOMEDICO scientists.

TITEL
STUDIE
JAHR
Evaluation of the metastatic colorectal cancer score (mCCS) in predicting outcome for patients with RAS wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Updated interim results of the non-interventional study VALIDATE

Reiser M, Marschner N, Uhlig J, Jacobasch L, Müller L, Schuch A, Serrer L, de Buhr RK, Siebenbach HU, Göhler T, Schröder J, Semsek D, Köhler A, Stübs P, Potthoff K

Download

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: ESMO / Journal:
VALIDATE
2023
Survival in patients with advanced renal cell carcinoma in the era of immunotherapies: first data from the German research platform CARAT

Goebell P.J., Bögemann M., Nusch A., Grünwald V., Müller L., von der Heyde E., Reichert D., Martens U.M., Grüllich C., Staehler M., Wetzel N., Koska M., Jänicke M., Marschner N., Potthoff K.

Oncol Res Treat. 2023;46 (Suppl. 5)(V510):76-77

Link

Indikation: Nierenzellkarzinom, Renal Cell Carcinoma / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CARAT
2023
Routine care of patients with resectable gastric (GC) and gastroesophageal junction (GEJC) adenocarcinoma – Data of the retrospective perioperative cohort PRIME of the registry platform SAPHIR

Lordick F., Dechow T., von der Heyde E., Sadjadian P., Schulte C., de Buhr R., Lennartz C., Binninger A., Jänicke M., Kruger S., Abromeit M., Lorenzen S., Reinacher-Schick A., Potthoff K.

Oncol Res Treat. 2023;46 (Suppl. 5)(V845):118

Link

Indikation: Gastric Cancer, Magenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
SAPHIR
2023
Behandlungsrealität und Outcome von PatientInnen mit lokal fortgeschrittenem, inoperablem (LAPC) und metastasiertem (MPC) Pankreaskarzinom – Daten aus dem klinischem Tumorregister Pankreaskarzinom (TPK)

Potthoff K., Hegewisch-Becker S., von der Heyde E., Heinemann V., Hof A., Binninger A., Glasstetter M., Jänicke M., Bürkle D., Dörfel S., Mohm J., Marschner N.

Oncol Res Treat. 2023;46 (suppl 5)(P691):241

Download

Indikation: Pancreatic Cancer, Pankreaskarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
TPK
2023
Real-World Data zur HER2-Testung und zur Therapie von PatientInnen mit einem HER2-positivem metastasiertem kolorektalem Karzinom – Daten aus der Registerplattform AZURITE

Bürkle D., Zahn M.-O., Sauer A., Michl M., Kullmann F., Schnell R., Hof A., Wetzel N., Boneva B., Jänicke M., Graf N., Neumann J., Stintzing S., Potthoff K.

Oncol Res Treat. 2023;46 (suppl 5)(V1021):158–9

Link

Indikation: Colorectal Cancer, Kolorektalkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
AZURITE
2023
1L maintenance therapy in patients with newly diagnosed advanced or metastatic ovarian cancer in routine care in Germany: results from the German registry platform SMARAGD

Juhasz-Böss I, Nusch A, Zaiss M, Fuchs R, Müller A, Jänicke M, u. a.

Oncol Res Treat. 2023;46 (suppl 5)(V1005):152–3

Link

Indikation: Ovarialkarzinom, Ovarian Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
SMARAGD
2023
SCLC patients treated with and without prophylactic cranial irradiation (PCI) in palliative setting after systemic treatment with checkpoint inhibitors (CPI) – Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-) Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315)

Reck M., Gauler T., Waller C.F., Fischer R., Christopoulos P., Bruch H.-R., Elender C., Ludwig P., Hipper A., Medinger T., Tech S., Binninger A., Jänicke M., Gleiber W., Hoknecht P., Sadjadian P., Griesinger F., Thomas M., Eberhardt W.E.E., Sebastian M.

Oncol Res Treat. 2023;46 (suppl. 5)(V46):7

Link

Indikation: Lung Cancer, Lungenkarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
CRISP
2023
Multiple myeloma: Antiresorptive therapy in patients with osteolytic lesions and impaired renal function – data from the MYRIAM registry

von der Heyde, Reiser, M., Nusch, A., Dechow, T., Jacobasch, L., Zingerle, M., Schweizer, C., Medinger, T., Jänicke, M., Potthoff, K., Engelhardt, M., Einsele, H., Knauf, W.

Oncol Res Treat 2023; 46 (suppl 5)(P1102), 313

Download

Indikation: Haemoblastoma, Hämoblastosen / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
MYRIAM
2023
Use of newly approved drugs for patients with early breast cancer (stage I-III) in Germany – data of the prospective, intersectoral research platform OPAL

Zahn M.-O., Decker T., Thoma M., Nusch A., Müller L., Zaiss M., Beurer B., Buss-Steidle R., Kruggel L., Lennartz C., Jänicke M., Gratzke K., Harbeck N., Wöckel A., Welt A., Thill M., Stickeler E.

Download

Indikation: Breast Cancer, Mammakarzinom / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
OPAL
2023
Systemic treatment of cholangiocellular carcinoma in Germany – Results from the prospective national intersectoral cohort study JADE

Freiberg-Richter J, Uhlig J, von der Heyde E, Schröder J, Pereira PL, Hofmann WP, et al.
Onco Targets Ther. 2023;46 (Suppl.5)(V309):354

Link

Indikation: Leberkrebs, Liver Cancer / Veranstaltung: DGHO / Journal: Oncology Research and Treatment
JADE
2023